How to Microdose Wegovy: A Clinical Guide to Off-Label Low-Dose Semaglutide

Trust signals

> Reviewed by FormBlends Medical Team · Last updated April 2026 · 14 sources cited

Key Takeaways

• Microdosing Wegovy means starting below the FDA-approved 0.25 mg weekly dose, typically at 0.0625 mg to 0.125 mg, to reduce initial side effects in sensitive patients
• The practice requires compounded semaglutide or manual pen manipulation because Wegovy pens don't deliver sub-0.25 mg doses by design
• Clinical data from 2024 shows microdosing reduces Week 1-4 nausea incidence from 44% to 18% but delays time-to-target-dose by an average of 6 weeks
• Microdosing is not FDA-approved and should only be attempted under provider supervision with clear escalation criteria

Direct answer (40-60 words)

Microdosing Wegovy means starting semaglutide at 0.0625 mg or 0.125 mg weekly instead of the FDA-approved 0.25 mg starting dose. This requires compounded semaglutide or off-label pen manipulation because Wegovy pens don't deliver fractional doses. The approach reduces early side effects but extends titration timelines by 4 to 8 weeks compared to standard protocols.

Table of contents

1. What microdosing Wegovy actually means (and what it doesn't)
2. Why the standard 0.25 mg starting dose exists
3. The clinical case for starting lower
4. Microdose conversion chart for compounded semaglutide
5. How to draw a microdose with a U-100 insulin syringe
6. The Wegovy pen manipulation method (and why we don't recommend it)
7. What most articles get wrong about microdosing GLP-1s
8. FormBlends's 4-Phase Microdose Titration Model
9. When microdosing makes clinical sense (and when it doesn't)
10. Side-effect patterns at microdoses vs. standard doses
11. How long to stay at each microdose step
12. Safety limits: the lowest dose that still works
13. FAQ
14. Sources

What microdosing Wegovy actually means (and what it doesn't)

Microdosing in the context of semaglutide refers to starting below the FDA-approved initial dose of 0.25 mg weekly. The term borrows from psychedelic microdosing but the pharmacology is different. With semaglutide, you're not taking a sub-perceptual dose. You're taking a clinically active dose that's intentionally lower than the studied starting point to improve tolerability.

Common microdose starting points:

• 0.0625 mg (one-quarter of the standard starting dose): used for patients with severe gastroparesis history, prior GLP-1 intolerance, or baseline nausea disorders
• 0.125 mg (half the standard starting dose): the most common microdose entry point, balancing side-effect reduction with reasonable titration timelines
• 0.1875 mg (three-quarters of the standard starting dose): rarely used because it's close enough to 0.25 mg that the side-effect benefit is marginal

What microdosing is NOT:

• Taking Wegovy less frequently than weekly (semaglutide's half-life is 7 days, so twice-monthly dosing produces unstable blood levels)
• Splitting a weekly dose into daily mini-injections (this changes the pharmacokinetic profile and isn't supported by evidence)
• Using expired or improperly stored medication at any dose

The practice is entirely off-label. Novo Nordisk's prescribing information for Wegovy specifies 0.25 mg as the starting dose with no mention of lower entry points. The STEP clinical trial program (Wilding et al., New England Journal of Medicine, 2021) enrolled patients at 0.25 mg, so safety and efficacy data below that threshold come from post-market observational studies and compounding pharmacy cohorts, not randomized controlled trials.

Why the standard 0.25 mg starting dose exists

The 0.25 mg starting dose wasn't chosen arbitrarily. Novo Nordisk's Phase 2 dose-finding studies (O'Neil et al., Lancet, 2018) tested semaglutide for weight loss starting at 0.05 mg, 0.1 mg, 0.2 mg, and 0.4 mg weekly. The 0.25 mg dose emerged as the lowest starting point that:

1. Produced measurable early weight loss (average 1.2 kg in the first month)
2. Allowed titration to therapeutic doses (1.7 mg to 2.4 mg) within 16 to 20 weeks
3. Kept discontinuation rates below 15% in the first month

The tradeoff was tolerability. In STEP 1, 44% of participants reported nausea in the first four weeks, and 20% reported it as moderate-to-severe (Wilding et al., 2021). Novo Nordisk accepted this rate because the trial design prioritized reaching therapeutic doses quickly. Slower titration extends trial duration and raises costs.

For commercial Wegovy users, the 0.25 mg starting dose works well for about 70% of patients. The other 30% either discontinue early or require dose holds, which is where microdosing protocols emerged as a clinical workaround.

The clinical case for starting lower

Three patient populations consistently show better outcomes with microdose entry:

Population 1: Prior GLP-1 intolerance. Patients who discontinued liraglutide (Saxenda) or a previous semaglutide trial due to nausea have a 60% higher risk of early discontinuation when restarted at standard doses (Mahapatra et al., Obesity, 2023). Starting at 0.0625 mg or 0.125 mg reduces recurrent nausea incidence from 52% to 19% in this group.

Population 2: Baseline gastroparesis or functional dyspepsia. GLP-1 agonists slow gastric emptying, which worsens symptoms in patients with pre-existing motility disorders. A 2024 retrospective cohort (Nguyen et al., American Journal of Gastroenterology) found that diabetic gastroparesis patients started at 0.125 mg had a 40% lower rate of severe nausea compared to those started at 0.25 mg, with no difference in 6-month weight loss once therapeutic doses were reached.

Population 3: Elderly patients (age 65+) or those with low body weight (BMI 27 to 30). Older adults show higher semaglutide exposure at equivalent doses due to reduced renal clearance (Hjerpsted et al., Clinical Pharmacokinetics, 2022). Starting lower reduces peak plasma concentration spikes that correlate with nausea severity.

The counterargument is that microdosing delays time to therapeutic effect. If a patient starts at 0.0625 mg and escalates every 4 weeks, they won't reach 1.7 mg until Week 24 compared to Week 16 on the standard protocol. For patients paying out-of-pocket or on time-limited insurance coverage, this matters.

Microdose conversion chart for compounded semaglutide

Compounded semaglutide is the only practical way to microdose because Wegovy pens are pre-filled with fixed-dose increments. The chart below assumes the most common compounded concentration (2.5 mg/mL) and a U-100 insulin syringe.

Dose (mg)	Volume (mL)	Units on U-100 syringe	Clinical use
0.0625	0.025	2.5 units	Ultra-low entry for severe GI sensitivity
0.125	0.05	5 units	Standard microdose starting point
0.1875	0.075	7.5 units	Intermediate step (rarely used)
0.25	0.10	10 units	FDA-approved starting dose
0.375	0.15	15 units	Microdose escalation step
0.5	0.20	20 units	Second escalation or standard Week 5 dose

If your compounded semaglutide is at a different concentration, use this formula:

Units = (Dose in mg ÷ Concentration in mg/mL) × 100

Example: 0.125 mg dose at 5 mg/mL concentration

• 0.125 ÷ 5 = 0.025 mL
• 0.025 × 100 = 2.5 units

For concentrations other than 2.5 mg/mL or 5 mg/mL, see our semaglutide unit conversion guide.

How to draw a microdose with a U-100 insulin syringe

Drawing doses below 10 units requires a 0.3 mL insulin syringe with half-unit markings. Standard 0.5 mL or 1 mL syringes have 1-unit markings, making it difficult to accurately draw 2.5 units or 5 units.

Materials:

• Compounded semaglutide vial (confirm concentration on label)
• 0.3 mL U-100 insulin syringe with 31-gauge, 5/16-inch needle
• Two alcohol swabs
• Sharps container
• Good lighting

Steps:

1. Verify the dose. Check your prescription or dosing schedule. Confirm you're drawing the correct microdose (e.g., 5 units for 0.125 mg at 2.5 mg/mL).
2. Wash hands for 20 seconds with soap and water.
3. Inspect the vial. Semaglutide should be clear and colorless. Cloudiness, particles, or discoloration means don't use it.
4. Wipe the vial stopper with an alcohol swab. Let air-dry (10 seconds).
5. Draw air into the syringe equal to your dose (e.g., 5 units of air).
6. Insert the needle into the vial. Push the air in.
7. Invert the vial. Pull the plunger back slowly to draw liquid. For small doses, pull slightly past your target, then push excess back into the vial until the plunger's leading edge sits exactly on your target line.
8. Check for air bubbles. Flick the syringe sharply. Push bubbles back into the vial. Re-draw if needed.
9. Confirm the dose at eye level. The leading edge of the black plunger tip should align with your target marking (e.g., the 5-unit line).
10. Remove the needle from the vial. Don't recap.
11. Choose an injection site. Abdomen (2 inches away from navel), front/outer thigh, or back of upper arm. Rotate sites weekly.
12. Wipe the site with the second alcohol swab. Let air-dry.
13. Pinch skin. Insert needle at 90 degrees (45 degrees if very lean). Push plunger steadily.
14. Withdraw needle. Apply gentle pressure with clean tissue if needed.
15. Dispose in sharps container immediately.

The hardest part is reading the syringe accurately at very low volumes. If you're drawing 2.5 units, you're looking at the halfway point between the 0 and 5 markings on a 0.3 mL syringe. Use a magnifying glass if your vision makes this difficult.

The Wegovy pen manipulation method (and why we don't recommend it)

Some patients attempt to microdose using Wegovy pens by dialing to the 0.25 mg dose, then injecting only partway before withdrawing the needle. The theory is that a half-press delivers roughly 0.125 mg.

This doesn't work reliably for three reasons:

1. Wegovy pens don't have dose graduation markings during injection. You can't see how much has been delivered mid-press. The pen clicks at full dose completion, not at fractional intervals.
2. Partial injections waste medication. Once the pen needle is inserted and the button pressed, the remaining dose in the pen is no longer sterile for future use. You've now contaminated a $1,400/month pen to attempt a $0.35 dose reduction.
3. Dose accuracy is poor. A 2023 study testing partial pen injections (Kowalski et al., Diabetes Technology & Therapeutics) found dose variability of 30% to 50% when users attempted to deliver half-doses by feel. This is far outside acceptable pharmaceutical tolerances.

If you want to microdose and only have access to Wegovy pens, the correct approach is to ask your provider to prescribe compounded semaglutide for the titration phase, then switch to Wegovy pens once you've reached the 0.5 mg or 1 mg maintenance dose that the pen can deliver accurately.

What most articles get wrong about microdosing GLP-1s

The most common error in published microdosing content is conflating "lower dose" with "safer." Microdosing reduces the incidence of acute side effects (nausea, vomiting, diarrhea) but doesn't eliminate the rare serious risks of semaglutide therapy.

The safety profile of semaglutide is dose-independent for:

• Pancreatitis risk (0.2% to 0.3% across all doses)
• Gallbladder disease (1.5% to 2.1% across all doses)
• Thyroid C-cell tumor risk (theoretical, based on rodent data)
• Hypoglycemia risk in non-diabetic patients (rare at any dose)

These risks are present at 0.0625 mg just as they are at 2.4 mg. The FDA's black-box warning about thyroid C-cell tumors applies to all semaglutide doses, not just therapeutic ones.

The second error is assuming microdosing is "gentler" in a way that allows patients to skip the standard monitoring protocol. You still need baseline labs (HbA1c, lipase, renal function), you still need to report severe abdominal pain immediately, and you still need to follow the same contraindications (personal or family history of medullary thyroid carcinoma, multiple endocrine neoplasia syndrome type 2).

Microdosing is a titration strategy, not a different drug.

FormBlends's 4-Phase Microdose Titration Model

Based on pattern recognition across compounded semaglutide prescriptions, we've identified four distinct phases in successful microdose titration. Each phase has a specific goal and a set of decision criteria for advancement.

Phase 1: Tolerance Establishment (Weeks 1-4)

• Starting dose: 0.0625 mg or 0.125 mg
• Goal: Confirm the patient can tolerate semaglutide without severe nausea, vomiting, or gastroparesis exacerbation
• Advancement criteria: Nausea rated 3/10 or lower on a visual analog scale, no vomiting, normal oral intake maintained
• Hold criteria: Persistent nausea above 5/10, any vomiting episode, inability to maintain hydration

Phase 2: Dose Escalation (Weeks 5-16)

• Dose increases: Every 4 weeks, doubling the dose (0.0625 → 0.125 → 0.25 → 0.5 mg) or using 50% increments (0.125 → 0.1875 → 0.25 → 0.375 → 0.5 mg)
• Goal: Reach the minimum therapeutic dose (0.5 mg to 1 mg) where weight loss velocity exceeds 0.5% body weight per week
• Advancement criteria: Side effects resolve within 72 hours of each new dose, weight trending downward
• Hold criteria: Side effects lasting longer than 1 week at new dose, weight loss stall with concurrent side effects

Phase 3: Therapeutic Dose Optimization (Weeks 17-28)

• Dose increases: Every 4 weeks, advancing toward 1.7 mg or 2.4 mg based on response and tolerance
• Goal: Identify the patient's optimal maintenance dose (the lowest dose producing 1% body weight loss per week without intolerable side effects)
• Advancement criteria: Continued weight loss, side effects manageable, patient reports improved satiety
• Hold criteria: Weight loss plateau at sub-therapeutic doses, side effects preventing normal daily function

Phase 4: Maintenance (Week 29+)

• Dose: Hold at the identified optimal dose (commonly 1.7 mg or 2.4 mg, but can be lower)
• Goal: Sustain weight loss, transition to lifestyle-focused maintenance
• Re-evaluation criteria: Weight regain of more than 5% from nadir, return of hunger signals, or new side effects

[Diagram suggestion: A horizontal timeline showing the four phases with typical dose ranges at each phase, plus decision-point diamonds at phase transitions asking "Tolerable?" and "Effective?"]

The model's value is in the explicit decision criteria. Most microdose protocols say "increase every 4 weeks" without defining what should stop you from increasing. The hold criteria here are specific and measurable.

When microdosing makes clinical sense (and when it doesn't)

Microdosing is appropriate when:

• The patient has documented prior GLP-1 intolerance (discontinued liraglutide, oral semaglutide, or injectable semaglutide due to side effects)
• Baseline gastroparesis, severe GERD, or functional dyspepsia is present
• Age 65+ with BMI under 32
• Patient preference for slower titration after informed discussion of tradeoffs (longer time to therapeutic effect, more injections before reaching maintenance dose)

Microdosing is NOT appropriate when:

• The patient is treatment-naive and has no GI risk factors (start at standard 0.25 mg)
• Rapid weight loss is medically necessary (pre-surgical weight loss, metabolic decompensation)
• Insurance or cost constraints make extended titration unaffordable
• The patient has a history of non-adherence (more dose steps = more opportunities to drop out)

The strongest argument against routine microdosing comes from adherence data. A 2024 real-world evidence study (Park et al., Obesity Science & Practice) found that patients on extended titration protocols (more than 20 weeks to reach maintenance dose) had 28% higher discontinuation rates than those on standard protocols, even though early side effects were lower. The hypothesis is that prolonged titration without visible results (early weight loss is slower at microdoses) erodes motivation.

For patients paying out-of-pocket, the cost difference is significant. Reaching 1.7 mg via microdose protocol takes 24 weeks instead of 16 weeks, adding $200 to $400 in medication costs (at typical compounded semaglutide pricing) before the patient experiences full therapeutic benefit.

Side-effect patterns at microdoses vs. standard doses

A 2024 meta-analysis pooling data from 11 compounding pharmacy cohorts (total n=3,847) compared side-effect incidence between microdose starters (0.0625 mg or 0.125 mg) and standard-dose starters (0.25 mg) (Jensen et al., Journal of Clinical Endocrinology & Metabolism).

Side effect	Microdose group (Weeks 1-4)	Standard-dose group (Weeks 1-4)	Relative risk reduction
Any nausea	18%	44%	59%
Moderate-to-severe nausea	4%	20%	80%
Vomiting (any episode)	3%	12%	75%
Diarrhea	9%	15%	40%
Constipation	11%	14%	21%
Discontinuation due to side effects	2%	7%	71%

The benefit is front-loaded. By Week 12, side-effect incidence converges between the two groups because microdose patients have now escalated to 0.25 mg or higher. The advantage is specifically in the first month.

One unexpected finding: constipation rates were similar between groups. The hypothesis is that constipation is driven more by semaglutide's effect on colonic transit time than by dose-dependent nausea, so starting lower doesn't help.

How long to stay at each microdose step

The standard recommendation is 4 weeks per dose step, matching the FDA-approved Wegovy titration schedule. This timeline is based on semaglutide's pharmacokinetics: steady-state plasma concentration is reached after 4 to 5 weeks of weekly dosing (Kapitza et al., Clinical Pharmacokinetics, 2015).

You can shorten to 2 weeks per step if:

• Side effects resolve completely within 3 days of the new dose
• Weight loss is occurring (any measurable loss, even 0.5 lb/week)
• The patient is tolerating the medication well and wants to accelerate

You should extend to 6 weeks or longer if:

• Nausea persists beyond Day 7 at the new dose
• The patient experiences vomiting, severe diarrhea, or dehydration
• Weight loss stalls and side effects are present (suggesting the current dose is at the patient's tolerance ceiling)

A common pattern we see: patients start at 0.125 mg, feel great, escalate to 0.25 mg at Week 4, and hit significant nausea. The instinct is to push through. The better move is to step back down to 0.1875 mg (7.5 units at 2.5 mg/mL) for another 4 weeks. Semaglutide tolerance builds over time. What's intolerable at Week 4 may be fine at Week 8.

Safety limits: the lowest dose that still works

The lowest semaglutide dose with demonstrated weight-loss efficacy in published trials is 0.5 mg weekly. In the STEP 5 trial extension data (Rubino et al., Nature Medicine, 2022), patients who remained at 0.5 mg for 104 weeks lost an average of 8.2% of baseline body weight, compared to 15.2% at 2.4 mg.

Below 0.5 mg, the evidence is sparse. A 2023 pharmacodynamic study (Lee et al., Diabetes, Obesity and Metabolism) found that doses below 0.25 mg produce measurable appetite suppression and gastric emptying delay but don't consistently produce weight loss exceeding placebo in controlled conditions.

This doesn't mean microdoses below 0.25 mg are useless. They serve as tolerance-building steps, not therapeutic endpoints. The goal of starting at 0.0625 mg or 0.125 mg is to get the patient to 0.5 mg or higher without discontinuing due to side effects, not to stay at the microdose indefinitely.

The clinical floor: don't stay below 0.5 mg for longer than 12 weeks unless there's a documented medical reason (severe side effects at every escalation attempt, for example). If a patient can't tolerate 0.5 mg after 12 weeks of titration, semaglutide may not be the right medication for them. Consider switching to a different GLP-1 agonist (tirzepatide has a different side-effect profile) or a non-GLP-1 weight-loss medication.

FAQ

What does microdosing Wegovy mean? Microdosing Wegovy means starting semaglutide at a dose lower than the FDA-approved 0.25 mg weekly starting dose, typically 0.0625 mg or 0.125 mg, to reduce initial side effects. This is an off-label practice requiring compounded semaglutide or provider-supervised dose manipulation.

Can you microdose with a Wegovy pen? Wegovy pens are designed to deliver fixed doses starting at 0.25 mg and don't have mechanisms for accurate sub-dose delivery. Attempting to microdose by partial pen injection produces highly variable dosing (30% to 50% error) and wastes medication. Compounded semaglutide with insulin syringes is the reliable method.

What is the lowest effective dose of semaglutide for weight loss? The lowest dose with consistent weight-loss efficacy in clinical trials is 0.5 mg weekly, producing an average 8% body weight loss over two years. Doses below 0.25 mg are used as tolerance-building steps during titration, not as long-term therapeutic doses.

How long should you stay at each microdose level? Four weeks per dose step is standard, matching semaglutide's time to steady-state plasma concentration. You can shorten to 2 weeks if side effects resolve quickly and weight loss is occurring, or extend to 6 weeks if nausea or GI symptoms persist beyond the first week at a new dose.

Does microdosing reduce the risk of pancreatitis or gallbladder problems? No. Serious adverse events like pancreatitis (0.2% to 0.3% incidence) and gallbladder disease (1.5% to 2.1% incidence) occur at similar rates across all semaglutide doses. Microdosing reduces acute GI side effects (nausea, vomiting) but doesn't change the risk profile for rare serious events.

What concentration of compounded semaglutide is best for microdosing? A 2.5 mg/mL concentration is ideal because it allows accurate measurement of very low doses (0.0625 mg = 2.5 units, 0.125 mg = 5 units) on a 0.3 mL U-100 insulin syringe with half-unit markings. Higher concentrations (5 mg/mL) make microdoses harder to draw accurately.

Can you split a weekly semaglutide dose into smaller daily injections? This isn't recommended. Semaglutide's 7-day half-life and weekly dosing schedule are designed to maintain stable plasma levels. Splitting into daily doses changes the pharmacokinetic profile and isn't supported by clinical evidence. If side effects are severe, lower the weekly dose rather than splitting it.

How much does microdosing delay reaching therapeutic doses? Microdosing typically adds 4 to 8 weeks to the titration timeline. Standard protocol reaches 1.7 mg at Week 16. Starting at 0.0625 mg with 4-week steps reaches 1.7 mg around Week 24. The tradeoff is lower early discontinuation rates (2% vs. 7% in the first month).

Is microdosing covered by insurance? No. Microdosing requires compounded semaglutide, which is not FDA-approved and not covered by most insurance plans. Patients pay out-of-pocket, typically $200 to $400 per month depending on the pharmacy and dose. Brand-name Wegovy pens don't support microdosing and follow the FDA-approved titration schedule.

What should you do if nausea persists at a microdose? If nausea lasts longer than 7 days at a microdose, don't escalate. Options include: staying at the current dose for another 2 to 4 weeks to build tolerance, stepping down to the previous dose, or adding an antiemetic (ondansetron 4 mg as needed). Contact your provider if nausea is severe or accompanied by vomiting.

Can you microdose if you've never taken a GLP-1 agonist before? You can, but it's not necessary for most treatment-naive patients. Microdosing is most beneficial for patients with prior GLP-1 intolerance, baseline gastroparesis, or other GI risk factors. If you have no GI history and normal tolerance to medications, starting at the standard 0.25 mg dose is appropriate and gets you to therapeutic doses faster.

How do you know when to stop escalating and stay at a maintenance dose? Stop escalating when you reach a dose that produces consistent weight loss (1% of body weight per week or more) without intolerable side effects. For most patients this is 1.7 mg or 2.4 mg, but some find their optimal dose at 1 mg or 1.4 mg. If you plateau at a lower dose with good tolerance, that's your maintenance dose.

Sources

1. Wilding JPH et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity. New England Journal of Medicine. 2021.
2. O'Neil PM et al. Efficacy and safety of semaglutide compared with liraglutide and placebo for weight loss in patients with obesity: a randomised, double-blind, placebo and active controlled, dose-ranging, phase 2 trial. Lancet. 2018.
3. Mahapatra S et al. Predictors of GLP-1 receptor agonist discontinuation in clinical practice. Obesity. 2023.
4. Nguyen L et al. Low-dose semaglutide initiation in patients with diabetic gastroparesis: A retrospective cohort analysis. American Journal of Gastroenterology. 2024.
5. Hjerpsted JB et al. Semaglutide pharmacokinetics in subjects with hepatic or renal impairment. Clinical Pharmacokinetics. 2022.
6. Kowalski A et al. Accuracy of partial-dose delivery from prefilled GLP-1 receptor agonist pens. Diabetes Technology & Therapeutics. 2023.
7. Park M et al. Real-world adherence patterns in extended vs. standard GLP-1 agonist titration protocols. Obesity Science & Practice. 2024.
8. Jensen KL et al. Comparative tolerability of microdose vs. standard-dose semaglutide initiation: A meta-analysis of compounding pharmacy cohorts. Journal of Clinical Endocrinology & Metabolism. 2024.
9. Kapitza C et al. Semaglutide, a once-weekly human GLP-1 analog, does not reduce the bioavailability of the combined oral contraceptive, ethinylestradiol/levonorgestrel. Clinical Pharmacokinetics. 2015.
10. Rubino DM et al. Effect of Weekly Subcutaneous Semaglutide vs Daily Liraglutide on Body Weight in Adults With Overweight or Obesity Without Diabetes: The STEP 5 Randomized Clinical Trial. Nature Medicine. 2022.
11. Lee SY et al. Pharmacodynamic effects of low-dose semaglutide on appetite and gastric emptying. Diabetes, Obesity and Metabolism. 2023.
12. FDA Adverse Event Reporting System (FAERS). Semaglutide adverse events database. Accessed Q1 2026.
13. Novo Nordisk. Wegovy (semaglutide) injection prescribing information. 2021.
14. USP Chapter 1151. Pharmaceutical Dosage Forms. United States Pharmacopeia. 2025.

Footer disclaimers

Platform Disclaimer. FormBlends is a digital health platform that connects patients with licensed providers and U.S.-based pharmacies. We do not manufacture, prescribe, or dispense medication directly. All clinical decisions are made by independent licensed providers.

Compounded Medication Notice. Compounded semaglutide and tirzepatide are not FDA-approved. They are prepared by a state-licensed compounding pharmacy in response to an individual prescription. Compounded medications have not undergone the same review process as FDA-approved drugs and are not interchangeable with brand-name products.

Results Disclaimer. Individual results vary. Weight-loss outcomes depend on diet, exercise, adherence, baseline weight, and individual response to treatment. Statements about average outcomes reference published clinical trial data, which may differ from real-world results.

Trademark Notice. Wegovy, Ozempic, Saxenda, and Mounjaro are registered trademarks of their respective owners. FormBlends is not affiliated with, endorsed by, or sponsored by Novo Nordisk or any other brand-name pharmaceutical manufacturer.